{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:51:43Z","timestamp":1784879503978,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) and its precursors monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) are 2\u20133 times more common in African Americans (AA) than European Americans (EA). Although epigenetic changes are well recognized in the context of myeloma cell biology, the contribution of 5-hydroxymethylcytosines (5hmC) to racial disparities in MM is unknown. Using the 5hmC-Seal and next-generation sequencing, we profiled genome-wide 5hmC in circulating cell-free DNA (cfDNA) from 342 newly diagnosed patients with MM (<jats:italic>n<\/jats:italic>\u2009=\u2009294), SMM (<jats:italic>n<\/jats:italic>\u2009=\u200918), and MGUS (<jats:italic>n<\/jats:italic>\u2009=\u200930). We compared differential 5hmC modifications between MM and its precursors among 227 EA and 115 AA patients. The captured 5hmC modifications in cfDNA were found to be enriched in B-cell and T-cell-derived histone modifications marking enhancers. Of the top 500 gene bodies with differential 5hmC levels between MM and SMM\/MGUS, the majority (94.8%) were distinct between EA and AA and enriched with population-specific pathways, including amino acid metabolism in AA and mainly cancer-related signaling pathways in EA. These findings improved our understanding of the epigenetic contribution to racial disparities in MM and suggest epigenetic pathways that could be exploited as novel preventive strategies in high-risk populations.<\/jats:p>","DOI":"10.1186\/s13045-022-01327-y","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T09:02:56Z","timestamp":1660640576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma"],"prefix":"10.1186","volume":"15","author":[{"given":"Brian C.-H.","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Karpus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangzhi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer S.","family":"Langerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Sukhanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parveen","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"issue":"7","key":"1327_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","volume":"8","author":"S Ailawadhi","year":"2018","unstructured":"Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, et al. Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials. Blood Cancer J. 2018;8(7):67.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1327_CR2","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1038\/s41467-020-20001-w","volume":"11","author":"XL Cui","year":"2020","unstructured":"Cui XL, Nie J, Ku J, Dougherty U, West-Szymanski DC, Collin F, et al. A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation. Nat Commun. 2020;11(1):6161.","journal-title":"Nat Commun"},{"issue":"1","key":"1327_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/ijc.32519","volume":"146","author":"S Margalit","year":"2020","unstructured":"Margalit S, Avraham S, Shahal T, Michaeli Y, Gilat N, Magod P, et al. 5-Hydroxymethylcytosine as a clinical biomarker: fluorescence-based assay for high-throughput epigenetic quantification in human tissues. Int J Cancer. 2020;146(1):115\u201322.","journal-title":"Int J Cancer"},{"issue":"3","key":"1327_CR4","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3324\/haematol.2019.222133","volume":"105","author":"F Chatonnet","year":"2020","unstructured":"Chatonnet F, Pignarre A, Serandour AA, Caron G, Avner S, Robert N, et al. The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation. Haematologica. 2020;105(3):774\u201383.","journal-title":"Haematologica"},{"issue":"10","key":"1327_CR5","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1093\/nar\/gkv387","volume":"43","author":"S Segalla","year":"2015","unstructured":"Segalla S, Pivetti S, Todoerti K, Chudzik MA, Giuliani EC, Lazzaro F, et al. The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA. Nucleic Acids Res. 2015;43(10):5182\u201393.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"1327_CR6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.2335","volume":"44","author":"KM Steinberg","year":"2012","unstructured":"Steinberg KM, Antonacci F, Sudmant PH, Kidd JM, Campbell CD, Vives L, et al. Structural diversity and African origin of the 17q21.31 inversion polymorphism. Nat Genet. 2012;44(8):872\u201380.","journal-title":"Nat Genet"},{"issue":"3","key":"1327_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/leu.2014.254","volume":"29","author":"Y Hou","year":"2015","unstructured":"Hou Y, Wang X, Li L, Fan R, Chen J, Zhu T, et al. FHL2 regulates hematopoietic stem cell functions under stress conditions. Leukemia. 2015;29(3):615\u201324.","journal-title":"Leukemia"},{"issue":"2","key":"1327_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cyto.2012.04.044","volume":"59","author":"CH Wong","year":"2012","unstructured":"Wong CH, Mak GW, Li MS, Tsui SK. The LIM-only protein FHL2 regulates interleukin-6 expression through p38 MAPK mediated NF-kappaB pathway in muscle cells. Cytokine. 2012;59(2):286\u201393.","journal-title":"Cytokine"},{"issue":"3","key":"1327_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1046\/j.1365-2257.2003.00511.x","volume":"25","author":"A Chehal","year":"2003","unstructured":"Chehal A, Taher A, Shamseddine A. IgM myeloma and Waldenstrom\u2019s macroglobulinemia: a distinct clinical feature, histology, immunophenotype, and chromosomal abnormality. Clin Lab Haematol. 2003;25(3):187\u201390.","journal-title":"Clin Lab Haematol"},{"issue":"4","key":"1327_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/bjh.12920","volume":"166","author":"C Hofmann","year":"2014","unstructured":"Hofmann C, Stuhmer T, Schmiedl N, Wetzker R, Mottok A, Rosenwald A, et al. PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform. Br J Haematol. 2014;166(4):529\u201339.","journal-title":"Br J Haematol"},{"issue":"5","key":"1327_CR11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/leu.2013.383","volume":"28","author":"W Zhou","year":"2014","unstructured":"Zhou W, Yang Y, Gu Z, Wang H, Xia J, Wu X, et al. ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia. 2014;28(5):1155\u20138.","journal-title":"Leukemia"},{"issue":"5","key":"1327_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41375-021-01234-0","volume":"35","author":"A Kassambara","year":"2021","unstructured":"Kassambara A, Herviou L, Ovejero S, Jourdan M, Thibaut C, Vikova V, et al. RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators. Leukemia. 2021;35(5):1451\u201362.","journal-title":"Leukemia"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01327-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01327-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01327-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T09:44:17Z","timestamp":1660902257000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01327-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1327"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01327-y","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"assertion":[{"value":"26 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of Chicago Institutional Review Board (Approval No. 10-178B and 14-0482).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.H. and W.Z. were shareholders of Epican Technology, Ltd, which held a license of the 5hmC-Seal technique from the University of Chicago for clinical applications. C.H. is the founder of Accent Therapeutics, Inc. and a member of its scientific advisory board. The remaining authors declare no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}